3 completed, 1 unknown. 2 Phase 2, 1 Phase 1, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow elexacaftor: new trials by email Literature Review of elexacaftor trials Research Report on elexacaftor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis Trikafta - Non-cystic Fibrosis Bronchiectasis | Phase 4 | Completed | Emory University | 32 | 2023-04-18 | 2026-02-09 |
| Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis. Elexacaftor 100 MG / Ivacaftor 75 MG / Tezacaftor 50 MG, 2 tablets each morning + Ivacaftor 150 mg one tablet each evening - Cystic Fibrosis | Unknown | CHC Montlegia | 20 | 2022-09-01 | 2022-10-31 | |
| Trikafta in Cystic Fibrosis Patients Trikafta - Cystic Fibrosis | Phase 2 | Completed | Emory University | 42 | 2019-09-04 | 2026-08-11 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
Cystic Fibrosis (3) · Signs and Symptoms, Respiratory (1)
Emory University (2) · CHC Montlegia (1) · Vertex Pharmaceuticals Incorporated (1)
United States (3) · Belgium (2) · Australia (1) · Netherlands (1)
Eric Sorscher, MD (2) · Patrick Lebecque, PhD (1)
PMID 30334692, PMID 33331662, PMID 37983082, PMID 39208836, PMID 39951444, PMID 42271629
2017 (1), R01HL139876 (1)